Undisclosed ERVs based cancer vaccine / Evaxion - LARVOL DELTA

Evaxion to present new data at AACR Annual Meeting (GlobeNewswire) - "One abstract will include new biomarker and immunogenicity data for cancer vaccine EVX-01....The data stems from the phase 2 trial investigating EVX-01 in combination with...KEYTRUDA (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology....The other abstract includes data on the use of AI-Immunology to identify endogenous retrovirus (ERV)-derived neoantigens to include in personalized vaccines to treat glioblastoma..."

Biomarker • P2 data • Preclinical • Glioblastoma • Melanoma

Evaxion establishes new AI-derived precision cancer vaccine concept (GlobeNewswire) - "New data confirming the preclinical PoC is presented at the ESMO Immuno-Oncology Congress, currently taking place in Geneva, Switzerland...This precision vaccine concept leverages our unique data insights and expertise in identifying vaccine targets compatible with the diversity of the immune system...The new data prove that the AI-Immunology platform can identify functional and potent ERV antigenic hotspots. This warrants further development towards clinical application...The new data stems from studies in human cell and mouse models. Stimulation with ERV precision vaccine targets induced ERV-specific T-cell responses in human immune cells from several donors. Further, AI-Immunology designed mouse ERV precision vaccines induced functional antigen-specific T-cells and inhibited tumor growth in mice."

Preclinical • Oncology

Evaxion announces 2025 milestones reflecting continued strong strategy execution (GlobeNewswire) - "Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025: All patients completed EVX-01 dosing - H1; Supplemental phase 2 biomarker and immunogenicity data - H1; Two-year phase 2 clinical efficacy readout - H2"

P2 data • Trial status • Melanoma • Oncology • Solid Tumor

Evaxion Announces Business Update and Third Quarter 2023 Financial Results (GlobeNewswire) - "Anticipated 2024 Milestones: (i) EVX-01 – Phase 2 one-year readout, Q3, 2024; (ii) Precision ERV cancer vaccines - Preclinical proof-of-concept obtained, H2, 2024."

P2 data • Preclinical • Melanoma